<DOC>
	<DOC>NCT00930059</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.</brief_summary>
	<brief_title>A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild to moderate Alzheimer's disease (MMSE 1426) Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed) Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study Significant cardiovascular disease in the past 6 months Illness other than Alzheimer's disease that could contribute to cognitive impairment History of stroke or seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>PF-04447943</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>plasma concentrations</keyword>
</DOC>